Mark For: IDL™ trademark registration is intended to cover the categories of vaccines, pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system, pharmaceutical preparations and substances acting on the central nervous system, central nervous system stimulants, pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases, pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, dyskinesia, poor or absent motor functions, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, headache, migraine, pain, alcoholism and chemical dependency, diagnostic agents, reagents, preparations and substances for medical purposes.
Status
2020-04-02 UTC
LIVE APPLICATION Awaiting Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
No
Intent To Use
No
Filed ITU
No
44D Filed
No
44E Current
Yes
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Claudia A. Smith
Attorney Docket Number
1101391-IDL
Timeline
2016-06-10
Trademark Registered
2020-03-30
Application Filed
2020-04-02
Location: NEW APPLICATION PROCESSING
2020-04-02
Status: Live/Pending
2020-04-02
Status: New application will be assigned to an examining attorney approximately 3 months after filing date.
CLAUDIA A. SMITH WHITE & CASE LLP 1221 AVENUE OF THE AMERICAS TRADEMARK DEPARTMENT NEW YORK, NY 10020
Good, Services, and Codes
International Codes:
5
U.S. Codes:
006,018,044,046,051,052
Type Code
Type
GS0051
Vaccines, pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system, pharmaceutical preparations and substances acting on the central nervous system, central nervous system stimulants, pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases, pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, dyskinesia, poor or absent motor functions, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, headache, migraine, pain, alcoholism and chemical dependency, diagnostic agents, reagents, preparations and substances for medical purposes
GS0051
Vaccines; pharmaceutical preparations for treatment and prevention of central nervous system diseases and disorders; pharmaceutical preparations acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations for the treatment and prevention of dementia, Alzheimer's disease and disorder, dizziness, seizures, strokes, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety disorder, apathy disorder, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, balance disorders, movement disorders and diseases, dyskinesia, motor disorder, tremors, schizophrenia, bipolar disorder and disease, mania, Attention Deficit Hyperactivity Disorder, Post Traumatic Stress Disorder, agitated major depressive disorder, intermittent explosive disorder, autism, melancholic depression, tourette's syndrome, progressive supranuclear palsy (PSP), restless leg syndrome, akathisia, chronic fatigue syndrome, somnolence, nausea, cancer, headache, migraine, pain, alcoholism and chemical dependency; diagnostic agents, preparations and substances for medical purposes
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.